Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report

Corrigendum in: /10.3892/mco.2017.1395

  • Authors:
    • Silun Xie
    • Jibing Chen
    • Mingjiie Zhang
    • Zhengyi Wu
  • View Affiliations

  • Published online on: April 28, 2017     https://doi.org/10.3892/mco.2017.1230
  • Pages: 903-906
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Masses are often detected in the abdomen of patients with sizeable ovarian cancer. There are currently no effective treatments available for late-stage ovarian cancer. Immunotherapy is gaining increasing attention worldwide in the clinical setting due to its ability to eliminate tumor cells and its favorable toxicity profile. We herein report the case of a 60-year-old woman who received allogenic natural killer (NK) cell immunotherapy for a sizeable ovarian carcinoma and achieved a noteworthy response. NK cells were isolated from the patient's own peripheral blood mononuclear cells, and the cell numbers were increased to 8-10 billion. The activated cells were expanded ex vivo for 14 days prior to intravenous infusion. After six infusions of NK cell therapy >3 months, the level of carbohydrate antigen 125 decreased significantly (from 11,270 to 580 U/ml). Furthermore, the size of the masses in the abdomen was markedly reduced. Overall, the treatment had few adverse effects and it prolonged patient survival. The present data and the patient response suggest that allogenic NK cell immunotherapy is a promising approach for ovarian cancer, with few treatment‑related adverse effects. The patient received six intravenous infusions of allogenic HANK cells between March, 2015 and June, 2015, but discontinued in October, 2015 and succumbed to the disease in March, 2016 following relapse.
View Figures
View References

Related Articles

Journal Cover

June 2017
Volume 6 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Xie, S., Chen, J., Zhang, M., & Wu, Z. (2017). Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Corrigendum in /10.3892/mco.2017.1395. Molecular and Clinical Oncology, 6, 903-906. https://doi.org/10.3892/mco.2017.1230
MLA
Xie, S., Chen, J., Zhang, M., Wu, Z."Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Corrigendum in /10.3892/mco.2017.1395". Molecular and Clinical Oncology 6.6 (2017): 903-906.
Chicago
Xie, S., Chen, J., Zhang, M., Wu, Z."Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Corrigendum in /10.3892/mco.2017.1395". Molecular and Clinical Oncology 6, no. 6 (2017): 903-906. https://doi.org/10.3892/mco.2017.1230